



**Network analysis identifies *Rv0324* and *Rv0880* as regulators of bedaquiline tolerance in *Mycobacterium tuberculosis***


**Supplementary Information**






**Supplementary Figure S1. Transcriptional response of MTB to bedaquiline treatment.** Volcano plot for the MTB bedaquiline transcriptome data. The fold-change is between the average of triplicate samples treated with bedaquiline and the average of untreated triplicate samples. The Benjamini Hochberg (BH) adjusted  $P$ -value comes from a  $t$ -test comparison of the sample groups.




**Supplementary Figure S2. Transcriptional response of *dosR* regulon and ATP synthase operon.** Heat maps showing the log<sub>2</sub> fold-change in gene expression of the *dosR* regulon (**a**) and ATP synthase operon (**b**) induced by bedaquiline treatment for 48-96 hrs as compared to untreated control from three biological samples. The color scale represents log<sub>2</sub> fold-change values.



**Supplementary Figure S3. Time-kill assays of wild type,  $\Delta rv0324$  and  $\Delta rv0880$  MTB strains with bedaquiline.** Raw CFUs over a period of 168 hours (7 days) with no bedaquiline (untreated, blue), 1.5  $\mu\text{M}$  bedaquiline (orange) or 15  $\mu\text{M}$  bedaquiline (green) comparing the H37Rv wild type (dashed lines) with the mutant strains (solid lines),  $\Delta rv0324$  (a) and  $\Delta rv0880$  (b). First-order rate kinetics were calculated by linear regression of CFUs from H37Rv wild type,  $\Delta rv0324$ , and  $\Delta rv0880$  strains obtained over 7 days of bedaquiline treatment (c). Statistical significance of rate kinetics between wild type and mutant strains were calculated using *t*-test, Benjamini Hochberg adjusted *P*-values are numbers in red. Error bars show the standard deviation from three biological samples (a and b) and the standard error of the linear regression (c). Representative results from two experiment repeats are presented. The same data (H37Rv wild type and 15  $\mu\text{M}$  bedaquiline) is shown for 96 hours in **Figure 2** of the manuscript. Bedaquiline, B.





**Supplementary Figure S4. Time-kill assays of wild type,  $\Delta rv0324$  and  $\Delta rv0880$  MTB strains with other antitubercular drugs.** Raw CFUs over a period of 96-120 hours with no antitubercular drug (untreated, dashed lines), 3x MIC of capreomycin (a), 3x MIC of pretomanid (b) or 3x MIC of rifampicin (c) comparing the H37Rv wild type MTB strain (black) with the  $\Delta rv0324$  (brown) and  $\Delta rv0880$  (teal) strains. Error bars show the standard deviation from three biological samples and the grey dashed line represents the limit of detection for the assay.







**Supplementary Figure S5. Transcriptional response of *rv0328* and *rv1049* regulons.**

Heat maps showing the log<sub>2</sub> fold-change in gene expression of the *rv0238* regulon (**a**) and *rv1049* regulon (**b**) induced by bedaquiline treatment for 48-96 hrs as compared to untreated control from three biological samples. The color scale represents log<sub>2</sub> fold-change values.




**Supplementary Figure S6. Killing of  $\Delta rv0238$  and  $\Delta rv1049$  MTB strains by bedaquiline.** CFUs over a period of 168 hours (7 days) with no bedaquiline (untreated, blue), 1.5  $\mu M$  bedaquiline (orange) or 15  $\mu M$  bedaquiline (green) comparing the H37Rv wild type (dashed lines) with the mutant strains (solid lines),  $\Delta rv0238$  (a) and  $\Delta rv1049$  (b). Error bars show the standard deviation from three biological samples. Bedaquiline, B.



**Supplementary Figure S7. Treatment of un-induced and induced rv0880 overexpression strain with bedaquiline-alone, pretomanid-alone, and bedaquiline and pretomanid in combination.** Mean log<sub>10</sub> CFU counts after 7 days of treatment with 0.3× MIC bedaquiline and 0.1× MIC pretomanid (a), 0.3× MIC bedaquiline and 0.3× MIC pretomanid (b), 1× MIC bedaquiline and 0.1× MIC pretomanid (c), and 1× MIC bedaquiline and 0.3× MIC pretomanid (d). Error bars show the standard deviation from three biological samples. Representative results from two experiment repeats are presented. Bedaquiline, B. Pretomanid, Pa.





**Supplementary Figure S8. The nutrient-limited conditional regulation of modules by *rv0324*.** The scatter plots show the correlation of log<sub>2</sub> fold-change in gene expression for *rv0324* versus the median of gene members of (a) module 420 ( $R = 0.97$ ,  $P$ -value =  $1.4 \times 10^{-5}$ ), (b) module 435 ( $R = 0.95$ ,  $P$ -value =  $9.8 \times 10^{-5}$ ), and (c) module 452 ( $R = 0.90$ ,  $P$ -value = 0.003) under limited nutrient growth conditions. Error bars show the standard deviation of module gene expression. The red line estimates the linear correlation between *rv0324* and module genes' expression; the grey area describes the standard error of the relationship.

	<b>H37Rv</b>	<b><math>\Delta rv0324</math></b>	<b><math>\Delta rv0880</math></b>	<b><i>rv0880</i> uninduced</b>	<b><i>rv0880</i> induced</b>
Bedaquiline MIC ( $\mu$ M)	2	2	2	0.5	0.5
Capreomycin MIC ( $\mu$ M)	2	1	2	0.5	0.5
Isoniazid MIC ( $\mu$ M)	1.8	1.8	1.8	1.8	1.8
Pretomanid MIC ( $\mu$ M)	0.42	0.42	0.42	0.42	0.21

**Supplementary Table S4. Comparative in vitro activity of antitubercular agents with H37Rv wild type and TF perturbation strains.** The MICs of four antitubercular agents for MTB wild type H37Rv,  $\Delta rv0324$ ,  $\Delta rv0880$ , and un-induced and induced *rv0880* overexpression strains. MICs were determined by the commercially available Bac Titer-Glo microbial cell viability assay kit. The MIC determinations were done with replicates in two (*rv0880* overexpression strain) or three (H37Rv,  $\Delta rv0324$ , and  $\Delta rv0880$  strains) independent experiments.

	<i>rv0324</i>	<i>rv0880</i>
Capreomycin 2× MIC	0.14	0.32
Capreomycin 4× MIC	2.83	0.82
Moxifloxacin 2× MIC	0.56	N.S.
Moxifloxacin 4× MIC	0.65	N.S.
Moxifloxacin 8× MIC	1.62	N.S.
Rifampin 1× MIC	N.S.	-0.23
Rifampin 2× MIC	N.S.	-0.11
Rifampin 4× MIC	N.S.	-0.6
Pretomanid 2× MIC	N.S.	-0.57
Pretomanid 4× MIC	N.S.	-0.73
Pretomanid 8× MIC	N.S.	-1.15
i030 2× MIC	0.15	N.S.
i030 4× MIC	0.17	N.S.
i030 8× MIC	0.64	N.S.
i031 2× MIC	0.71	N.S.
i031 4× MIC	1.6	N.S.
i047 2× MIC	0.63	N.S.
i047 4× MIC	0.65	N.S.

**Supplementary Table S5. Antitubercular agents with significant differential expression of *rv0324* or *rv0880* in MTB.** The table displays prioritized drugs from mining transcriptome data of 36 antitubercular agents for significant alteration of the expression of *rv0324* or *rv0880* ( $P$ -value < 0.01). The IsoGene R package was used to test the monotone relationship between gene expression and drug dosage.  $P$ -values were calculated based on a resampling procedure in which the distribution of the statistic under the null hypothesis is approximated using permutations. The values in the table are log<sub>2</sub> fold-change (GSE71200). Not significant, N.S.